Twice-yearly HIV Prevention: Lenacapavir and Access in South Africa
Lenacapavir adds a longer-acting HIV prevention option. Understand testing, follow-up and why rollout news does not mean every clinic already provides it.
WHO reported South Africa’s lenacapavir prevention rollout in June 2026. A twice-yearly injectable option can broaden prevention choices, but it still requires appropriate assessment, HIV testing and scheduled follow-up. This guide does not imply that our practice supplies it.
Prevention and treatment are different
PrEP is medicine used by people without HIV to reduce the chance of acquiring it. It is not a substitute for HIV treatment in someone who already has HIV, and it is different from emergency PEP after a possible exposure. A clinician needs to confirm which pathway applies before treatment. Tell the service about recent exposures, symptoms of illness and previous HIV tests rather than choosing a product solely on the convenience of its injection schedule.
Access depends on the rollout service
National announcements do not guarantee immediate stock or eligibility at every public or private facility. Ask a local HIV prevention service which options it currently offers, who can receive them and how assessment is arranged. If lenacapavir is not available to you, ask about other appropriate prevention choices rather than delaying protection. Keep a record of the clinic and follow-up plan. Avoid buying an injectable product from an unverified online seller or assuming an overseas prescription applies locally.
Long-acting does not mean no follow-up
A prevention programme includes HIV testing and discussion of ongoing exposure, adverse effects and injection timing. Ask what happens if you miss an appointment, need to transfer clinics or want to stop. Because a long-acting medicine remains in the body, the transition plan matters. Tell the clinician about all other medicines and any pregnancy or breastfeeding considerations. Ask who to contact between visits and how to obtain your prevention record if you move or change providers.
Keep prevention broader than one medicine
PrEP does not prevent pregnancy or every other STI. Condoms, appropriate STI screening, contraception when needed and clear information about partners’ HIV treatment remain part of a personalised plan. If a possible exposure has just occurred and protection is uncertain, seek urgent PEP assessment immediately; PEP must begin within 72 hours and works best when started sooner. Do not wait for a routine PrEP booking or a future rollout appointment. Prevention decisions should reflect your circumstances without stigma or assumptions about your relationships.
Key Takeaways
- Lenacapavir expands prevention choice but requires clinical assessment.
- Availability and eligibility must be confirmed with the service.
- Keep testing and injection follow-up appointments.
- Recent possible exposure may require urgent PEP instead.
Sources & further reading
General health information; speak with a qualified healthcare professional for advice about your own care.